BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Market Closed - Bid/Ask 01:35:29 2024-05-20 pm EDT | After market 03:52:36 pm | |||
| 986.2 EUR | +2.29% |
|
990.2 | +0.41% |
| Current month | +1.96% | ||
| 1 month | +17.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 986.2 | +2.29% |
| 24-05-17 | 964.1 | -1.04% |
| 24-05-16 | 974.2 | -1.31% |
| 24-05-15 | 987.1 | +6.52% |
| 24-05-14 | 926.7 | +1.04% |
Real-time Boerse Frankfurt Warrants
Last update May 20, 2024 at 01:35 pm EDT
More quotesStatic data
| Product type | Certificats Bonus |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD423P |
| ISIN | DE000HD423P1 |
| Date issued | 2024-03-22 |
| Strike | 1,250 $ |
| Maturity | 2024-12-20 (214 Days) |
| Parity | 1 : 1 |
| Emission price | 926.2 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,002 € |
|---|---|
| Lowest since issue | 814 € |
| Spread | 0.07 € |
| Spread % | 0.01% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- Certificat
